Direct interactions with influenza promote bacterial adherence during respiratory infections.


Journal

Nature microbiology
ISSN: 2058-5276
Titre abrégé: Nat Microbiol
Pays: England
ID NLM: 101674869

Informations de publication

Date de publication:
08 2019
Historique:
received: 10 09 2018
accepted: 04 04 2019
pubmed: 22 5 2019
medline: 22 1 2020
entrez: 22 5 2019
Statut: ppublish

Résumé

Epidemiological observations and animal models have long shown synergy between influenza virus infections and bacterial infections. Influenza virus infection leads to an increase in both the susceptibility to secondary bacterial infections and the severity of the bacterial infections, primarily pneumonias caused by Streptococcus pneumoniae or Staphylococcus aureus. We show that, in addition to the widely described immune modulation and tissue-remodelling mechanisms of bacterial-viral synergy, the virus interacts directly with the bacterial surface. Similar to the recent observation of direct interactions between enteric bacteria and enteric viruses, we observed a direct interaction between influenza virus on the surface of Gram-positive, S. pneumoniae and S. aureus, and Gram-negative, Moraxella catarrhalis and non-typeable Haemophilus influenzae, bacterial colonizers and pathogens in the respiratory tract. Pre-incubation of influenza virus with bacteria, followed by the removal of unbound virus, increased bacterial adherence to respiratory epithelial cells in culture. This result was recapitulated in vivo, with higher bacterial burdens in murine tissues when infected with pneumococci pre-incubated with influenza virus versus control bacteria without virus. These observations support an additional mechanism of bacteria-influenza virus synergy at the earliest steps of pathogenesis.

Identifiants

pubmed: 31110359
doi: 10.1038/s41564-019-0447-0
pii: 10.1038/s41564-019-0447-0
pmc: PMC7069060
mid: NIHMS1068694
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1328-1336

Subventions

Organisme : NIAID NIH HHS
ID : HHSN272201400006C
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA021765
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI110618
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI124302
Pays : United States

Références

Pediatr Res. 2005 Dec;58(6):1198-203
pubmed: 16306193
J Infect Pulm Dis. 2016 Oct;2(2):
pubmed: 27981251
Science. 2011 Oct 14;334(6053):249-52
pubmed: 21998395
EMBO Mol Med. 2014 Jan;6(1):141-54
pubmed: 24408968
Nat Rev Microbiol. 2018 Jun;16(6):355-367
pubmed: 29599457
Infect Immun. 2013 Dec;81(12):4498-508
pubmed: 24082069
Eur J Clin Microbiol Infect Dis. 2018 Sep;37(9):1725-1733
pubmed: 30033505
mBio. 2017 Jun 6;8(3):
pubmed: 28588131
Nat Rev Microbiol. 2016 Apr;14(4):197-204
pubmed: 26853118
J Infect Dis. 2011 Dec 15;204(12):1857-65
pubmed: 21930608
Vaccine. 2009 Feb 18;27(8):1192-200
pubmed: 19135117
mSphere. 2017 Oct 11;2(5):
pubmed: 29034326
Cell Host Microbe. 2017 Jan 11;21(1):73-83
pubmed: 28081446
Cell Host Microbe. 2018 Jan 10;23(1):77-88.e5
pubmed: 29290575
Pediatr Res. 2007 Apr;61(4):398-403
pubmed: 17515861
Viruses. 2018 Jan 03;10(1):
pubmed: 29301335
Infect Immun. 2016 Aug 19;84(9):2714-22
pubmed: 27400721
J Infect Dis. 2013 Aug 1;208(3):432-41
pubmed: 23661797
J Gen Virol. 2015 Sep;96(9):2557-2568
pubmed: 26297001
Epidemiol Infect. 2016 Nov;144(15):3226-3236
pubmed: 27405603
J Infect Dis. 2014 Nov 15;210(10):1649-57
pubmed: 24907383
Infect Immun. 2007 Jun;75(6):3102-11
pubmed: 17403870
Am J Respir Crit Care Med. 2014 Jul 15;190(2):196-207
pubmed: 24941423
J Bacteriol. 2005 Jul;187(13):4627-36
pubmed: 15968074
J Infect Dis. 1994 Oct;170(4):867-72
pubmed: 7523537
Clin Microbiol Infect. 2013 Feb;19(2):113-8
pubmed: 23231363
Science. 2016 Jan 15;351(6270):
pubmed: 26816384
PLoS Pathog. 2017 Dec 6;13(12):e1006768
pubmed: 29211815
J Immunol. 2013 Aug 1;191(3):1250-9
pubmed: 23804714
Nat Rev Microbiol. 2014 Apr;12(4):252-62
pubmed: 24590244
Clin Infect Dis. 2014 May;58(10):1369-76
pubmed: 24621951
Clin Microbiol Rev. 2003 Apr;16(2):230-41
pubmed: 12692096
mBio. 2011 Sep 20;2(5):
pubmed: 21933918
Cell Host Microbe. 2014 Jan 15;15(1):36-46
pubmed: 24439896
J Infect Dis. 2015 Jul 15;212(2):195-201
pubmed: 25505300
Mol Microbiol. 2006 Feb;59(3):961-74
pubmed: 16420364
Ann Otol Rhinol Laryngol. 2009 Nov;118(11):769-72
pubmed: 19999361
J Med Microbiol. 2007 Sep;56(Pt 9):1133-1137
pubmed: 17761473
J Virol. 2011 Dec;85(23):12262-70
pubmed: 21917948
Infect Immun. 1995 Apr;63(4):1153-7
pubmed: 7890365
Clin Infect Dis. 2008 Mar 15;46(6):815-23
pubmed: 18279042
J Infect Dis. 2002 Aug 1;186(3):341-50
pubmed: 12134230
FEMS Immunol Med Microbiol. 1999 Apr;23(4):331-41
pubmed: 10225293

Auteurs

Hannah M Rowe (HM)

Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.

Victoria A Meliopoulos (VA)

Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.

Amy Iverson (A)

Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.

Perrine Bomme (P)

Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.
UtechS Ultrastructural Bioimaging, Institut Pasteur, Paris, France.

Stacey Schultz-Cherry (S)

Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.

Jason W Rosch (JW)

Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA. Jason.Rosch@stjude.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH